Trial Profile
CS-801 phase 3 long-term study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Jun 2016
Price :
$35
*
At a glance
- Drugs Oxybutynin (Primary)
- Indications Overactive bladder
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sankyo
- 10 Jun 2016 New trial record